RxDoctor Payments Data

Nusrat Shafi, MD

Family Medicine · Columbia, SCNPI 1083802490

Payments from drug & device makers

$616in general payments, 2019–2025

Across 29 payments — averaging $21.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$310
  • AbbVie$88
  • Eisai Inc.$61
  • AstraZeneca$43
  • Arbor Pharmaceuticals, Inc.$26
  • Alfasigma USA, Inc.$23
  • plus $64 from 4 others

What the payments were for

  • Food & beverage$616100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk11$310
AbbVie(2 entities)5$88
Eisai Inc.3$61
AstraZeneca3$43
Arbor Pharmaceuticals, Inc.2$26
Alfasigma USA, Inc.1$23
Amgen1$20
Mannkind Corporation1$19
Sanofi Pasteur Inc.1$13
Lilly USA, LLC1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$616 in reported general payments places this provider in the 50th percentile of 2,153 family medicine providers in South Carolina.

See all family medicine providers in South Carolina

Medicare billing

Part B allowed, 2024
$50,163
Medicare patients
161
Services billed
603

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RybelsusSemaglutide16$34,135
OzempicSemaglutide31$30,554
JanuviaSitagliptin Phosphate11$16,894
Lantus SolostarInsulin Glargine,hum.Rec.Anlog43$4,738
Atorvastatin Calcium136$1,229
Gabapentin61$1,071
Metformin Hcl169$964
Rosuvastatin Calcium53$928
Amlodipine Besylate157$892
Pantoprazole Sodium70$800
Levothyroxine Sodium69$788
Losartan Potassium65$773
Albuterol Sulfate HfaAlbuterol Sulfate29$758
Simvastatin85$739
Omeprazole57$665

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskRybelsus, Ozempic$310$64,68947 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 2,153 family medicine providers in South Carolina.

Other family medicine in Columbia

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →